Trial · NCT01794143
Results by group16
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 16 of 16
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Time to HbA1c>=7%, While Receiving Metformin and the Randomly Assigned Glucose-lowering Study Medication | Glargine Insulin U-100 | 1.3 | Inter-Quartile Range 0.6 to 2.5 | years | |
| Time to HbA1c>=7%, While Receiving Metformin and the Randomly Assigned Glucose-lowering Study Medication | Glimepiride | 1.3 | Inter-Quartile Range 0.6 to 2.3 | years | |
| Time to HbA1c>=7%, While Receiving Metformin and the Randomly Assigned Glucose-lowering Study Medication | Liraglutide | 1.5 | Inter-Quartile Range 0.6 to 2.7 | years | |
| Time to HbA1c>=7%, While Receiving Metformin and the Randomly Assigned Glucose-lowering Study Medication | Sitagliptin | 0.8 | Inter-Quartile Range 0.5 to 2.0 | years | |
| Time to HbA1c>7.5%, While Receiving Metformin and the Randomly Assigned Glucose-lowering Study Medication. | Glargine Insulin U-100 | 2.1 | Inter-Quartile Range 1.0 to 3.5 | years | |
| Time to HbA1c>7.5%, While Receiving Metformin and the Randomly Assigned Glucose-lowering Study Medication. | Glimepiride | 2.0 | Inter-Quartile Range 1.1 to 3.3 | years | |
| Time to HbA1c>7.5%, While Receiving Metformin and the Randomly Assigned Glucose-lowering Study Medication. | Liraglutide | 2.2 | Inter-Quartile Range 1.0 to 3.5 | years | |
| Time to HbA1c>7.5%, While Receiving Metformin and the Randomly Assigned Glucose-lowering Study Medication. | Sitagliptin | 1.7 | Inter-Quartile Range 0.8 to 3.0 | years | |
| HbA1c>=7%, While Receiving Metformin and the Randomly Assigned Glucose-lowering Study Medication | Glargine Insulin U-100 | 852 | Participants | ||
| HbA1c>=7%, While Receiving Metformin and the Randomly Assigned Glucose-lowering Study Medication | Glimepiride | 908 | Participants | ||
| HbA1c>=7%, While Receiving Metformin and the Randomly Assigned Glucose-lowering Study Medication | Liraglutide | 860 | Participants | ||
| HbA1c>=7%, While Receiving Metformin and the Randomly Assigned Glucose-lowering Study Medication | Sitagliptin | 981 | Participants | ||
| HbA1c>7.5%, While Receiving Metformin and the Randomly Assigned Glucose-lowering Study Medication. | Glargine Insulin U-100 | 498 | Participants | ||
| HbA1c>7.5%, While Receiving Metformin and the Randomly Assigned Glucose-lowering Study Medication. | Glimepiride | 633 | Participants | ||
| HbA1c>7.5%, While Receiving Metformin and the Randomly Assigned Glucose-lowering Study Medication. | Liraglutide | 583 | Participants | ||
| HbA1c>7.5%, While Receiving Metformin and the Randomly Assigned Glucose-lowering Study Medication. | Sitagliptin | 697 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01794143/results